Watson claims that its Oxycodone Hydrochloride extended-release tablets are the generic version of Purdue Pharma’s treatment, OxyContin for the management of moderate to severe when continuous, around-the-clock opioid analgesic is needed for an extended period of time.
Purdue Pharma filed a lawsuit against Watson in the in the US District Courts for the Southern District of New York, District of Delaware and Southern District of Florida, to restrict the company for commercializing the drug prior to the expiration of the US patents numbers 6,488,963, 7,674,799, 7,674,800, 7,683,072 and 7,776,314.